Stories about Hazard ratio

Subscribe to Hazard ratio

02.03.2020 – 08:01

Merck KGaA
ERBITUX® Approved for First-line Use in China in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)

Darmstadt, Germany (ots/PRNewswire) - Approval is for ERBITUX® in combination with platinum-based therapy with fluorouracil for the first-line treatment of R/M SCCHN Pivotal Phase III study shows significant improvements with ERBITUX® in combination with platinum-based therapy with fluorouracil in response rate, ...

more
28.10.2019 – 19:00

Merck KGaA
European Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma

Darmstadt, Germany, and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media -- EU approval based on JAVELIN Renal 101 trial results demonstrating significant improvement in progression-free survival with BAVENCIO in combination with axitinib compared with sunitinib -- Combination regimen ...

more
11.06.2019 – 20:45

Novo Nordisk A/S
Oral semaglutide demonstrated cardiovascular safety in people with type 2 diabetes and established cardiovascular disease or high cardiovascular risk in PIONEER 6 trial

San Francisco (ots/PRNewswire) - Novo Nordisk today announced that the PIONEER 6 trial achieved its primary endpoint by demonstrating non-inferiority of major adverse cardiovascular events (MACE) with oral semaglutide compared with placebo, both in addition to standard of care. The primary endpoint was defined as ...

more
16.02.2019 – 23:10

Merck KGaA
Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine

Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media - JAVELIN Renal 101 shows significant improvement in progression-free survival with a hazard ratio of 0.69 in patients regardless of PD-L1 expression - US FDA has granted Priority Review to BAVENCIO plus INLYTA for ...

more
28.08.2018 – 16:39

Thrombosis Research Institute
Real-world Evidence From GARFIELD-AF Shows Superior Reduction in Mortality With Non-vitamin K Antagonists Oral Anticoagulants (NOACs) vs. Vitamin K Antagonists (VKAs) in Newly Diagnosed Atrial Fibrillation

Munich (ots/PRNewswire) - - High-risk patients on anticoagulants (AC) for stroke prevention also have 17% fewer deaths over 2 years of follow-up than patients who are not treated with AC - Patients who receive AC plus add-on antiplatelet therapy (AP) for stroke prevention have a significantly worse prognosis than ...

more
26.08.2018 – 14:00

Novo Nordisk A/S
Ozempic® Consistently Reduced the Risk of Major Cardiovascular Events Across Type 2 Diabetes Populations at High CV Risk Regardless of Prior CV Events at Baseline

Munich (ots/PRNewswire) - Ozempic® (semaglutide) consistently reduced the risk of the composite outcome of time to first occurrence of non-fatal heart attack, non-fatal stroke or cardiovascular death (collectively termed major adverse cardiovascular events, MACE) in people with type 2 diabetes at high ...

more
08.08.2018 – 18:40

Kyowa Kirin International PLC
Kyowa Kirin Announces FDA Approval of Poteligeo® (mogamulizumab-kpkc) for the Treatment of Mycosis Fungoides and Sézary Syndrome

Tokyo (ots/PRNewswire) - - Poteligeo has been approved for the treatment of the two most common types of Cutaneous T-cell lymphoma (CTCL) in previously treated patients based on data showing improved progression-free survival (PFS) and overall response rate (ORR) when compared to vorinostat. - FDA approval was based ...

more
24.03.2015 – 12:26

Astellas Pharma Europe Limited
Astellas Announces New Enzalutamide Data Presented During Plenary Presentations at the 2015 European Association of Urology Congress

London (ots/PRNewswire) - Astellas Pharma Europe Ltd. today announced new data from the Phase 2 TERRAIN trial of enzalutamide compared to bicalutamide in metastatic castration-resistant prostate cancer (CRPC), as well as an updated overall survival analysis from the placebo-controlled Phase 3 PREVAIL trial of ...

more
22.10.2013 – 13:00

Astellas Pharma Europe Limited
Medivation and Astellas Announce the Phase 3 PREVAIL Trial of XTANDI?(TM) (Enzalutamide) Meets Both Co-Primary Endpoints of Overall Survival and Radiographic Progression-Free Survival in Chemotherapy-Naïve Patients with Advanced Prostate Cancer

Tokyo And San Francisco (ots/PRNewswire) - - Study will be stopped early and enzalutamide offered to all qualified study participants - 30% Reduction in the Risk of Death, Hazard Ratio = 0.70 ...

more

1